Mutual Funds that own CSL Ltd.
Vanguard Total International Stock Index Fund
6,413,185
1.42%
83,272
0.3%
07/31/2018
American Funds EuroPacific Growth Fund
4,640,000
1.03%
0
0.54%
06/30/2018
Government Pension Fund - Global (The)
4,333,353
0.96%
587,726
0.08%
12/31/2017
First State Investments ICVC - Asia Pacific Leaders Fund
3,691,497
0.82%
0
5.13%
01/31/2018
Fidelity Series International Growth Fund
3,623,666
0.8%
-229,772
4.12%
07/31/2018
Vanguard Australian Shares Index Fund
3,280,842
0.73%
51,811
5.95%
07/31/2018
Oppenheimer International Growth Fund
2,876,000
0.64%
-123,300
1.8%
05/31/2018
Vanguard Developed Markets Index Fund
2,548,765
0.56%
-2,052
0.38%
07/31/2018
iShares MSCI EAFE ETF
2,230,904
0.49%
0
0.52%
09/06/2018
WCM Focused International Growth Fund
1,811,824
0.4%
-341,370
5.01%
04/30/2018
| Address |
45 Poplar Road
Parkville Victoria (VIC) 3052
Australia
|
|
Employees
|
- |
| Website |
http://www.csl.com.au |
| Updated |
07/08/2019 |
| CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. |
